Comparing cemiplimab treatments for advanced basal cell skin cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This study tests different ways of using the drug cemiplimab to treat advanced basal cell skin cancer that cannot be removed with surgery or treated with radiation. It aims to find the most effective approach to shrink or control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with basal cell skin cancer that has spread locally but not to distant parts of the body.
- You have at least one tumor that is at least 1 centimeter (about the size of a pea) that can be measured.
- Your doctor has said that surgery or radiation is not a good option for you, or you have chosen not to have them.
- You have not taken any previous treatments for this cancer, such as hedgehog inhibitor drugs or other systemic therapies.
- You are generally in good health, able to care for yourself, and have no significant heart problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests cemiplimab, an immunotherapy drug, as a first treatment for advanced basal cell carcinoma that cannot be removed with surgery or radiation. The goal is to see if it can shrink or control the cancer.
This trial tests combining a skin cream (imiquimod), a laser treatment, and an immunotherapy drug (cemiplimab) before surgery for high-risk basal cell carcinoma. The goal is to see if this combination shrinks tumors enough to make surgery less disfiguring or damaging to nearby functions.
This trial tests a drug (cemiplimab) injected directly into early-stage skin cancer (squamous cell carcinoma) to see if it can shrink or cure the cancer before surgery. It may help patients avoid more extensive surgery or reduce the chance of the cancer coming back.
This trial compares two treatments for advanced melanoma that cannot be removed with surgery or has spread. It studies how these treatments affect the immune response in tumors and blood, and requires extra biopsies and blood draws.
This early-phase study tests cemiplimab (an immune therapy that helps your immune system attack cancer) given before surgery. It aims to shrink tumors and improve outcomes for people with Merkel cell cancer or certain locally advanced skin squamous cell cancers (CSCC).
This trial tests whether adding the immunotherapy drug cemiplimab to standard treatment can help people with advanced lung cancer that has already progressed after both platinum chemo and a prior immunotherapy. It is designed for those who responded to their first immunotherapy for at least 12 weeks before the cancer started growing again.
Hear when a new Locally Advanced Basal Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.